Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Elliott

Gastroenterology Fort Myers, FL Doctor of Osteopathy

NPI 1811986581 CMS profile 263656

16410 Healthpark Commons Dr, Fort Myers, FL 33908

Open in the dashboard

General payments

$7,541

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Elliott of Fort Myers, FL is reported in the CMS Open Payments database as having received $7,541 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,538 37
2024 General $1,223 29
2023 General $557 29
2022 General $1,074 53
2021 General $1,187 62
2020 General $599 28
2019 General $1,363 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Elliott
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Elliott were reported at $1,538. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Elliott Gastroenterology median Middle half National median
2019 $1,363 $417 $126–$1,100 $163
2020 $599 $224 $74–$624 $114
2021 $1,187 $352 $106–$1,054 $132
2022 $1,074 $448 $129–$1,270 $149
2023 $557 $533 $150–$1,390 $160
2024 $1,223 $605 $160–$1,606 $164
2025 $1,538 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,695 74 payments
  2. Janssen Biotech, Inc. $1,341 46 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $739 39 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $469 19 payments
  5. Gilead Sciences, Inc. $430 18 payments
  6. Pfizer Inc. $391 13 payments
  7. Braintree Laboratories, Inc. $347 35 payments
  8. Celgene Corporation $295 23 payments
  9. Madrigal Pharmaceuticals $281 2 payments
  10. Exact Sciences Corporation $200 3 payments
  11. Other $1,352 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,264 297 payments
  2. Education $277 27 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $861 14 payments
  2. STELARA $824 38 payments
  3. XIFAXAN $677 36 payments
  4. CREON $478 19 payments
  5. HUMIRA $398 21 payments
  6. LINZESS $382 19 payments
  7. VELSIPITY $356 11 payments
  8. SKYRIZI $353 8 payments
  9. ENTYVIO $304 12 payments
  10. ZEPOSIA $295 23 payments
  11. Other $3,756 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

961

Median for Gastroenterology: 569

Drug cost

$397,664

Median for Gastroenterology: $104,976

Branded share of claims

26.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 35 $239,061
Linzess Linaclotide Brand 47 $54,291
Creon Lipase/Protease/Amylase Brand 16 $48,914
Movantik Naloxegol Oxalate Brand 12 $13,554
Mesalamine Generic 30 $7,943
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 33 $4,653
Pantoprazole Sodium Generic 332 $4,277
Mercaptopurine Generic 33 $3,636
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 21 $3,584
Cholestyramine Cholestyramine (With Sugar) Brand 34 $3,048

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$123,457

Medicare's payments for the services billed

Medicare patients

593

Average age 76

Services billed

1,161

307 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 43%
COPD 32%
Depression 31%
Diabetes 30%
Atrial fibrillation 30%
Chronic kidney disease 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VELSIPITY
  • PFIZER INC. $157
$157 — —
SKYRIZI
  • AbbVie, Inc. $154
$155 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $136
$136 — —
TREMFYA
  • Janssen Biotech, Inc. $128
$128 — —
STELARA
  • Janssen Biotech, Inc. $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record